Bristol Myers Squibb (CELG-RI) Asset Utilization Ratio (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Asset Utilization Ratio of 0.56 for Q2 2026, up 10.8% year-over-year from 0.51 in Q2 2025, and up 2.85% quarter-over-quarter from 0.55 in Q1 2026.
Bristol Myers Squibb (CELG-RI) Asset Utilization Ratio (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Asset Utilization Ratio for 17 consecutive years, with 0.56 the latest figure, recorded in Q2 2026.
- In Q2 2026, Asset Utilization Ratio rose 10.8% year-over-year to 0.56; the TTM figure through Jun 2026 stood at 0.56 (up 10.8% YoY), while the FY2025 annual figure was 0.53, up 2.58% from the prior year.
- Asset Utilization Ratio rose to 0.56 in Q2 2026 per CELG-RI's latest filing, from 0.55 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.56 in Q2 2026 and bottomed at 0.44 in Q1 2022.
- Historically, Asset Utilization Ratio has averaged 0.49 across 5 years, with a median of 0.48 in 2023.
- Annual changes were most pronounced in 2022 — Asset Utilization Ratio increased 19.29% — and 2024, when it retreated 2.26%.
- Bristol Myers Squibb's Asset Utilization Ratio stood at 0.47 in 2022, then climbed by 2.0% to 0.48 in 2023, then climbed by 7.4% to 0.52 in 2024, then slipped by 0.57% to 0.52 in 2025, then rose by 9.57% to 0.56 in 2026.
- Business Quant data shows CELG-RI's Asset Utilization Ratio at 0.56 in Q2 2026, 0.55 in Q1 2026, and 0.52 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 0.49 |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 0.47 |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 0.52 |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 0.53 |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 0.40 |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 0.58 |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 0.31 |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 0.64 |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 0.56 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.56 |
| Mar 31, 2026 | 0.55 |
| Dec 31, 2025 | 0.52 |
| Sep 30, 2025 | 0.50 |
| Jun 30, 2025 | 0.51 |
| Mar 31, 2025 | 0.51 |
| Dec 31, 2024 | 0.52 |
| Sep 30, 2024 | 0.50 |
| Jun 30, 2024 | 0.48 |
| Mar 31, 2024 | 0.47 |
| Dec 31, 2023 | 0.48 |
| Sep 30, 2023 | 0.49 |
| Jun 30, 2023 | 0.48 |
| Mar 31, 2023 | 0.48 |
| Dec 31, 2022 | 0.47 |
| Sep 30, 2022 | 0.47 |
| Jun 30, 2022 | 0.46 |
| Mar 31, 2022 | 0.44 |
| Dec 31, 2021 | 0.42 |
| Sep 30, 2021 | 0.41 |